Evotec, Celgene in neurodegenerative discovery deal

Evotec AG (Xetra:EVT) and Celgene Corp. (NASDAQ:CELG) began a five-year deal to discover and develop therapies to treat neurodegenerative diseases including amyotrophic lateral sclerosis, Alzheimer's disease and Parkinson's disease.

The deal is based on Evotec's induced pluripotent stem cell (iPSC) platform. Celgene will receive options to obtain exclusive, worldwide rights to programs developed from Evotec's compound library. Celgene may also screen compounds from its own CELMoD library in patient-derived disease models using Evotec's iPSC platform...